Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antigenics Inc.
Antigenics Presents Positive Oncophage® Interim Survival Data at ASCO
June 17th, 2009
Antigenics Inc. (NASDAQ: AGEN) announced results of an interim analysis from the company’s ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46 percent lower risk of death when treated with Oncophage® (vitespen) cancer vaccine compared with observation (n = 362; P = 0.036; hazard ratio [HR] = 0.54). Christopher G. Wood, MD, associate professor of urology at M. D. Anderson Cancer Center in Houston and lead US investigator, presented the survival results at the annual meeting of the American Society of Clinical Oncology (ASCO; abstract # 3009). ...
Source: Vaccine Weekly (2009-06-17)
|
